Posts Tagged ‘insurance coverage’
August 27, 2024 — That was quick. At about 6 am today, we posted to say that obesity drug prices are stuck in the spotlight. “Bold leadership on obesity drug pricing and access to care is the only thing that will bring relief from this uncomfortable spotlight,” we wrote. Before the end of the hour, Lilly took the cue. […]
June 20, 2024 — It’s quite weird, actually, watching the contortions of health plans as they twist to resist the rising tide of obesity medicines. Because despite the twisting and contortions, obesity medicines are as difficult to resist as a rising tide. Those who pretend it is not happening find themselves under water. A new survey from the International […]
November 17, 2023 — It’s not easy. Getting access to good obesity care and maintaining it is a challenge that is especially frustrating as we see that the options for care are improving. But it seems that health systems right now are rigged to interrupt obesity treatment. An illustration of this comes from a recent study published in Obesity. […]
August 11, 2023 — Calm in the midst of a storm is always odd. Has it passed? Or is there more to come? Bedlam pretty much defines the market for obesity care right now. Both Novo Nordisk and Lilly announced robust business results on the strength of impressive new options for treating obesity. Novo released stunning topline results for […]
August 3, 2023 — Message to University of Texas Employees: Continuing to pay for obesity medicines is unsustainable. Message from Novo Nordisk: No comment. Price shocks for advanced obesity medicines are hitting employers. Things are starting to get messy in the marketplace and you can be pretty sure that they will only get messier as makers of obesity medicines […]
March 14, 2023 — Recently, we have written much about the high cost of obesity medicines, limited coverage under health plans, and the need for change. This is a very real problem and glaciers melt faster (sad to say) than policy makers make progress on this. But absurd arguments about the cost of obesity care do not help. In […]